Search Results

Business

NeoPhore appoints Dr Matthew Baker as VP Immunology

NeoPhore Limited, a small molecule cancer immuno-oncology company, announces the appointment of Dr Matthew Baker as VP Immunology to the company’s management team.

July 8, 2019

·

2 min read

Business

NeoPhore Appoints Pioneering Cancer Researchers and Clinicians to Scientific Advisory Board

NeoPhore today announced the formation of its Scientific Advisory Board, featuring internationally-renowned experts in the fields of cancer genetics, translational clinical oncology and immuno-oncology.

January 8, 2018

·

2 min read

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company

Sixth Element Capital LLP announces a £3 million investment in NeoPhore, a spin out from Cambridge, UK based PhoreMost Ltd

November 15, 2017

·

1 min read

Business

NeoPhore appoints Dr John Haurum as Non-Executive Director

Former F-star CEO joins the Board of Directors

March 20, 2019

·

2 min read

NeoPhore Scientific Founders Publish Breakthrough Immuno-Oncology Discoveries in Nature

Clinical and now lab data suggest that many cancers with defective DNA repair appear to be highly sensitive to immune surveillance, including when the immune system is modified with agents that disrupt immune “checkpoints”.

November 30, 2017

·

2 min read

Four Biotechs Bringing Home the Bacon for Cancer Therapies, Vaccines and MRSA

Investment dollars continue to flood the life sciences industry as new technologies and groundbreaking approaches tear down the dams that have previously hindered advancement.

March 12, 2021

·

4 min read

·

Kate Goodwin

Business

STORM Therapeutics appoints Dr John Haurum to the Board of Directors

STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, announced the appointment of Dr John Haurum as an independent Non-Executive Director with immediate effect.

June 27, 2019

·

2 min read